Budge Kelly, Dellepiane Sergio, Yu Samuel Mon-Wei, Cravedi Paolo
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Front Med (Lausanne). 2021 Jan 21;7:599236. doi: 10.3389/fmed.2020.599236. eCollection 2020.
Currently available treatments of diabetic kidney disease (DKD) remain limited despite improved understanding of DKD pathophysiology. The complement system is a central part of innate immunity, but its dysregulated activation is detrimental and results in systemic diseases with overt inflammation. Growing evidence suggests complement activation in DKD. With existent drugs and clinical success of treating other kidney diseases, complement inhibition has emerged as a potential novel therapy to halt the progression of DKD. This article will review DKD, the complement system's role in diabetic and non-diabetic disease, and the potential benefits of complement targeting therapies especially for DKD patients.
尽管对糖尿病肾病(DKD)病理生理学的认识有所提高,但目前可用的DKD治疗方法仍然有限。补体系统是固有免疫的核心部分,但其失调激活是有害的,并导致伴有明显炎症的全身性疾病。越来越多的证据表明DKD中存在补体激活。鉴于现有药物以及治疗其他肾脏疾病的临床成功,补体抑制已成为一种潜在的新型疗法,以阻止DKD的进展。本文将综述DKD、补体系统在糖尿病和非糖尿病疾病中的作用,以及补体靶向治疗特别是对DKD患者的潜在益处。